TC BioPharm (Holdings) PLC (NASDAQ: TCBP) shares lost some ground Monday, as the Edinburgh-based clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, announced the first Cohort B patient in the ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 in Acute Myeloid Leukemia, has completed the full dosing regiment.
This morning’s news release reported the ACHIEVE trial is an open-label Phase II study dedicated to evaluating the efficacy and safety of TCB008. This trial is focused on assessing the treatment’s effectiveness and tolerability on patients suffering from acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS/AML) with challenging cases such as refractory or relapsed conditions.
Cohort B recruits patients who have achieved remission following previous treatment yet continue to have a detectable or minimal residual disease (MRD).
Recruitment into Cohort B was initiated during the fourth quarter of 2024, ahead of the Company’s anticipated schedule. The first Cohort B patient received their dose in October 2024. The initial Cohort B patient has completed the dosing regiment, receiving all four planned doses of TCB008, and is expected to receive an additional fifth dose. Enrolment of a second Cohort B patient has also been initiated.
TCPB shares ditched 26 cents, or 6.5%, to $3.77.
